Transdermal stimulants prior authorization
Customize your policy alerts
Sign up for allcareadvantage Policy 095.2 alerts
Get alerted when Policy 095.2 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization requirements for coverage of transdermal stimulant products (e.g., Daytrana, Xelstrym) for treatment of ADHD in members, including approval and renewal criteria and quantity limits.
Coverage Criteria
Initial Therapy — Covered when ALL of the following are met in sequence per the policy decision flow:
Covered when ALL of the following are met in sequence per the policy decision flow:
If step 3 met -> Approve. If step 3 not met and step 4 met -> Approve. If step 3 not met and step 4 not met -> Deny.
Continuation/Renewal
Renewal approval requires:
If improvement documented -> Approve renewal; if not documented -> Deny.
Requests for transdermal stimulant coverage under this policy exclude members who are not within the age range of 6–18 years. If the member is outside this 6–18 year range, the request is denied per the stated criteria.
Coding and Limits
| Daytrana | methylphenidate transdermal |
| Xelstrym | dextroamphetamine transdermal system |
Provider Actions and Requirements
Prior authorization required — transdermal stimulants
Prior authorization is required for transdermal stimulant products (Daytrana, Xelstrym). Approvals are granted only when all clinical and step criteria are met, including member age 6–18 and documentation of ADHD with moderate-to-severe functional impairment; prior trial/failure of a formulary long‑acting oral stimulant is required unless contraindicated or the member cannot use/absorb oral formulations.
- Covered agents listed: Daytrana (methylphenidate) and Xelstrym (dextroamphetamine transdermal system).
- Approval length: up to 1 year; quantity limit: 1 per day.
Step therapy — trial of long‑acting oral stimulant required
Before a transdermal stimulant will be approved, the member must have tried and failed a formulary long‑acting oral stimulant formulation; if there is a documented contraindication or the member cannot swallow/absorb oral stimulants, the requirement is waived.
- If trial/failure of formulary long‑acting oral stimulant is documented → Approve.
- If no trial/failure but a documented contraindication or inability to swallow/absorb oral stimulants is provided → Approve; otherwise → Deny.
Required documentation to support approval
Submit documentation that supports an ADHD diagnosis and shows moderate‑to‑severe continuing functional disturbance using an appropriate ADHD symptom rating scale (e.g., Conners‑Wells Adolescent Self‑Report, Conners Comprehensive Behavior Rating Scale, Child Behavior Checklist). Also document prior trial and failure of a formulary long‑acting oral stimulant or a contraindication/inability to swallow or absorb oral stimulants.
- Use an appropriate ADHD symptom rating scale for ages 6–18 to document functional impairment.
- Include records showing trial and failure of formulary long‑acting oral stimulants or clinical rationale for inability to use them.
Triggers for denial
Requests will be denied if the member is not between 6 and 18 years of age, if submitted documentation does not support a diagnosis of ADHD with moderate‑to‑severe functional impairment on an appropriate rating scale, or if step therapy criteria (trial/failure of a formulary long‑acting oral stimulant) or documented contraindication/inability are not met.
- Member outside age 6–18 → Deny.
- Documentation does not support ADHD with moderate‑to‑severe functional impairment → Deny.
- No trial/failure of formulary long‑acting oral stimulant and no documented contraindication/inability → Deny.
Background
Attention‑Deficit/Hyperactivity Disorder (ADHD) is a childhood‑onset neurodevelopmental condition characterized by inattention, hyperactivity, and impulsivity that impair functioning across settings. Transdermal stimulant products referenced in this policy (e.g., Daytrana, Xelstrym) are FDA‑approved for treatment of ADHD in patients age 6 years and older and are considered when oral long‑acting stimulants are unsuitable or have failed. The policy requires documentation of an ADHD diagnosis with moderate‑to‑severe continuing functional disturbance measured by an appropriate ADHD symptom rating scale (for example, Conners or the Child Behavior Checklist) and applies step therapy and prior authorization requirements before approval of transdermal therapy.
Definitions
Transdermal Stimulant Therapy
Transdermal stimulant therapy
Agents listed are non-preferred; approval follows prior authorization and step requirements.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.